Literature DB >> 11071504

Paroxetine in Parkinson's disease: effects on motor and depressive symptoms.

R Ceravolo1, A Nuti, A Piccinni, G Dell'Agnello, G Bellini, G Gambaccini, L Dell'Osso, L Murri, U Bonuccelli.   

Abstract

Selective serotonin reuptake inhibitors have been used in the treatment of depression in patients with PD. Conflicting data as to whether selective serotonin reuptake inhibitors worsen parkinsonian motor symptomatology have been reported. In this study, the additional 6 months therapy with paroxetine 20 mg/d in a group of depressed patients with PD did not modify parkinsonian motor function (Unified Parkinson's Disease Rating Scale scores); however, in one patient, fully reversible worsening of tremor was observed. Depression, as evaluated by Beck Depression Inventory and Hamilton Depression Rating Scale, improved from baseline to final visit (p < 0.05 by analysis of variance).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071504     DOI: 10.1212/wnl.55.8.1216

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors:  D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Treatment options for tauopathies.

Authors:  Tarik Karakaya; Fabian Fußer; David Prvulovic; Harald Hampel
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

3.  Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.

Authors:  Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

4.  Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

Authors:  Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

5.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 6.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

Review 8.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

9.  Using Canadian Primary Care Sentinel Surveillance Network data to examine depression in patients with a diagnosis of Parkinson disease: a retrospective cohort study.

Authors:  Kimberly Rose P Singian; Morgan Price; Vicky Bungay; Sabrina T Wong
Journal:  CMAJ Open       Date:  2016-08-08

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.